Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

5.76USD
3:59pm EST
Change (% chg)

$-0.15 (-2.54%)
Prev Close
$5.91
Open
$5.90
Day's High
$5.92
Day's Low
$5.54
Volume
1,253,751
Avg. Vol
843,483
52-wk High
$6.96
52-wk Low
$2.51

SGYP.OQ

Chart for SGYP.OQ

About

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin... (more)

Overall

Beta: 1.71
Market Cap(Mil.): $1,063.53
Shares Outstanding(Mil.): 179.95
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -1.23 -- --
ROI: -159.24 -1.38 14.86
ROE: -- -1.07 16.28

BRIEF-Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation

* Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation

Jan 19 2017

Synergy wins U.S. approval for constipation drug

The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 19 2017

UPDATE 1-Synergy wins U.S. approval for constipation drug

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).

Jan 19 2017

Synergy wins U.S. approval for constipation drug

Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC). (http://bit.ly/2k5wNlA)

Jan 19 2017

BRIEF-FDA approves Trulance for chronic idiopathic constipation

* FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc Source text for Eikon: Further company coverage:

Jan 19 2017

Synergy Pharma's irritable bowel drug succeeds in key study

Synergy Pharmaceuticals Inc said its experimental once-daily tablet, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.

Dec 09 2016

BRIEF-Synergy Pharma enters privately-negotiated exchange agreements

* Synergy Pharma-co entered privately-negotiated exchange agreements with certain holders of co's 7.50% convertible senior notes due 2019

Nov 21 2016

BRIEF-Synergy Pharmaceuticals Inc reports qtrly loss per share of $0.22

* Synergy Pharmaceuticals reports third quarter 2016 financial results and business update Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-Synergy Pharma files for common stock offering of up to $17.2 million - sec filing

* Synergy Pharmaceuticals files for common stock offering of up to $17.2 million - Sec filing Source text for Eikon: Further company coverage:

Oct 06 2016

BRIEF-Synergy Pharmaceuticals announces new plecanatide data presentations

* Synergy Pharmaceuticals announces new plecanatide data presentations at upcoming scientific meeting and provides update on IBS-C program

Sep 28 2016

Earnings vs. Estimates